Literature DB >> 19100788

Activation of c-Jun-N-terminal kinase in a rat model of intracerebral hemorrhage: the role of iron.

Shu Wan1, Renya Zhan, Shusen Zheng, Ya Hua, Guohua Xi.   

Abstract

Iron accumulates in the brain and contributes to brain injury after intracerebral hemorrhage (ICH). The c-Jun-N-terminal kinase (JNK) signaling pathway mediates cell death after ischemic stroke, however, the involvement of JNK in ICH is not well known. This study investigated whether the JNK signaling pathway is activated by iron after ICH. Male Sprague-Dawley rats received an infusion of autologous whole blood (as a model of ICH) or ferrous iron into the right basal ganglia and control rats had an infusion of saline. Some ICH rats were treated with either deferoxamine (DFX), an iron chelator, or vehicle. Activation of JNK was measured by Western blot analysis and immunohistochemistry. Free iron in cerebrospinal fluid (CSF) and behavioral outcomes following ICH were also examined. We found that activated JNK in the brain were increased after ICH, and an intracerebral infusion of ferrous iron also upregulated brain activated JNK. Free iron accumulated in CSF and systemic administration of DFX after ICH reduces free iron contents in CSF, suppresses JNK activation and improves ICH-induced neurological deficits. Our results demonstrated that the JNK signaling pathway is activated after ICH and iron may contribute to this activation. DFX reduces free iron levels and attenuates activation of JNK suggesting iron chelation may be useful therapy for ICH patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19100788      PMCID: PMC2649665          DOI: 10.1016/j.neures.2008.10.013

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  32 in total

1.  Hemoglobin potentiates central nervous system damage.

Authors:  S M Sadrzadeh; D K Anderson; S S Panter; P E Hallaway; J W Eaton
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

2.  Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs.

Authors:  P D Hurn; R C Koehler; K K Blizzard; R J Traystman
Journal:  Stroke       Date:  1995-04       Impact factor: 7.914

3.  Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage.

Authors:  Takehiro Nakamura; Richard F Keep; Ya Hua; Timothy Schallert; Julian T Hoff; Guohua Xi
Journal:  J Neurosurg       Date:  2004-04       Impact factor: 5.115

4.  Neurotoxicity of hemoglobin in cortical cell culture.

Authors:  R F Regan; S S Panter
Journal:  Neurosci Lett       Date:  1993-04-30       Impact factor: 3.046

5.  Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats.

Authors:  C Palmer; R L Roberts; C Bero
Journal:  Stroke       Date:  1994-05       Impact factor: 7.914

6.  The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia.

Authors:  Shuzo Okuno; Atsushi Saito; Takeshi Hayashi; Pak H Chan
Journal:  J Neurosci       Date:  2004-09-08       Impact factor: 6.167

7.  Deferoxamine improves early postresuscitation reperfusion after prolonged cardiac arrest in rats.

Authors:  Serguei Liachenko; Pei Tang; Yan Xu
Journal:  J Cereb Blood Flow Metab       Date:  2003-05       Impact factor: 6.200

8.  Iron and iron-handling proteins in the brain after intracerebral hemorrhage.

Authors:  Jimin Wu; Ya Hua; Richard F Keep; Takehiro Nakamura; Julian T Hoff; Guohua Xi
Journal:  Stroke       Date:  2003-11-13       Impact factor: 7.914

Review 9.  Heme and iron metabolism: role in cerebral hemorrhage.

Authors:  Kenneth R Wagner; Frank R Sharp; Timothy D Ardizzone; Aigang Lu; Joseph F Clark
Journal:  J Cereb Blood Flow Metab       Date:  2003-06       Impact factor: 6.200

Review 10.  Heme oxygenase-1: unleashing the protective properties of heme.

Authors:  Leo E Otterbein; Miguel P Soares; Kenichiro Yamashita; Fritz H Bach
Journal:  Trends Immunol       Date:  2003-08       Impact factor: 16.687

View more
  15 in total

1.  Metformin Attenuates Neurological Deficit after Intracerebral Hemorrhage by Inhibiting Apoptosis, Oxidative Stress and Neuroinflammation in Rats.

Authors:  Boxiang Qi; Libao Hu; Lei Zhu; Lei Shang; Xuecheng Wang; Na Liu; Nana Wen; Yao Hong; Daihua Fang
Journal:  Neurochem Res       Date:  2017-06-29       Impact factor: 3.996

2.  Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice.

Authors:  Bihua Wu; Qingyi Ma; Hidenori Suzuki; Chunhua Chen; Wenwu Liu; Jiping Tang; John Zhang
Journal:  Neurocrit Care       Date:  2011-02       Impact factor: 3.210

3.  Deferoxamine reduces intracerebral hemorrhage-induced white matter damage in aged rats.

Authors:  Wei Ni; Masanobu Okauchi; Tetsuhiro Hatakeyama; Yuxiang Gu; Richard F Keep; Guohua Xi; Ya Hua
Journal:  Exp Neurol       Date:  2015-03-04       Impact factor: 5.330

Review 4.  Experimental intracerebral hemorrhage: avoiding pitfalls in translational research.

Authors:  Matthew A Kirkman; Stuart M Allan; Adrian R Parry-Jones
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-24       Impact factor: 6.200

5.  Ferric iron chelation lowers brain iron levels after intracerebral hemorrhage in rats but does not improve outcome.

Authors:  Angela M Auriat; Gergely Silasi; Zhouping Wei; Rosalie Paquette; Phyllis Paterson; Helen Nichol; Frederick Colbourne
Journal:  Exp Neurol       Date:  2011-12-27       Impact factor: 5.330

6.  Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response.

Authors:  Cassie Bennett; Farrah Mohammed; Anabel Álvarez-Ciara; Michelle A Nguyen; W Dalton Dietrich; Suhrud M Rajguru; Wolfgang J Streit; Abhishek Prasad
Journal:  Biomaterials       Date:  2018-10-18       Impact factor: 12.479

7.  High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods.

Authors:  Sharon D Yeatts; Yuko Y Palesch; Claudia S Moy; Magdy Selim
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

Review 8.  Efficacy of deferoxamine in animal models of intracerebral hemorrhage: a systematic review and stratified meta-analysis.

Authors:  Han-Jin Cui; Hao-yu He; A-Li Yang; Hua-Jun Zhou; Cong Wang; Jie-Kun Luo; Yuan Lin; Tao Tang
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

9.  The protective role of (-)-epigallocatechin-3-gallate in thrombin-induced neuronal cell apoptosis and JNK-MAPK activation.

Authors:  Qianqian He; Lei Bao; Jeffrey Zimering; Kun Zan; Zuohui Zhang; Hongjuan Shi; Jie Zu; Xinxin Yang; Fang Hua; Xinchun Ye; Guiyun Cui
Journal:  Neuroreport       Date:  2015-05-06       Impact factor: 1.837

10.  Regulation of Th1 T Cell Differentiation by Iron via Upregulation of T Cell Immunoglobulin and Mucin Containing Protein-3 (TIM-3).

Authors:  Christa Pfeifhofer-Obermair; Piotr Tymoszuk; Manfred Nairz; Andrea Schroll; Gloria Klais; Egon Demetz; Sabine Engl; Natascha Brigo; Günter Weiss
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.